Regression of Established Breast Carcinoma Xenografts with Antibody-directed Enzyme Prodrug Therapy against c-erbB2 p185

Cancer Research

Volumn 54, Issue 19, 1994, Pages 5171-5177

  Eccles, Suzanne A ^a   Court, William J ^a   Box, Gary A ^a   Dean, Christopher J ^a   Melton, Roger G ^b   Springer, Caroline J ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c CRC Centre for Cancer Therapeutics   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

[4 [(2 CHLOROETHYL)(2 MESYLOXYETHYL)AMINO]BENZOYL]GLUTAMIC ACID; CARBOXYPEPTIDASE; IMMUNOGLOBULIN G2; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER REGRESSION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTO ONCOGENE;

ANIMAL; ANTIBODIES, MONOCLONAL; FEMALE; GAMMA-GLUTAMYL HYDROLASE; HUMAN; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM TRANSPLANTATION; PRODRUGS; RATS; RECEPTOR, ERBB-2; SUPPORT, NON-U.S. GOV'T; TRANSPLANTATION, HETEROLOGOUS;

EID: 0027942213     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Bagshawe, K. D. Antibody directed enzymes revive anti-cancer prodrug concept. Br. J. Cancer, 56: 531-532, 1987.
2. Bagshawe, K. D., Springer, C. J., Searle, F., Antoniw, P., Sharma, S. K., Melton, R. G., and Sherwood, R. F. A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer, 58: 700-703, 1988.
3. Scnter, P. D., Wallace, P. M., Svensson, H. P., Vrudhula, V. M., Kerr, D. E., Hellström, I., and Hellström, K. E. Generation of cytotoxic agents by targeted enzymes. Bioconjugate Chcm. 4: 3-9, 1993.
4. Springer, C. J., Antoniw, P., Bagshawe, K.D.M. Searle, F., Bisset, G.M.F. and Jarman, M. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J. Med. Chem. 33: 677-681, 1990.
5. Springer, C. J., Bagshawe, K. D., Sharma, S. K., Searle, F., Boden, J. A., Antoniw, P., Burke, P. J., Rogers, G. T., Sherwood, R. F., and Melton, R. G. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur. J. Cancer, 27: 1361-1366, 1991.
6. Bagshawe, K. D., Sharma, S. K., Springer, C. J., Antoniw, P., Boden, J. A., Rogers, G. T., Burke, P. J., Melton, R. G., and Sherwood, R. F. Antibody-directed enzyme prodrug therapy (ADEPT): clinical report. Dis. Markers, 9; 233-238, 1991.
7. Frei, E. HI. Curative cancer chemotherapy. Cancer Res. 45: 6532-6538, 1985.
8. Scnter, P. D., Saulnier, M. G., Schreiber, G. J., Hirshberg, D. L., Brown, J. P., Hellström, I., and Hellström, K. E. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc. Natl. Acad. Sci. USA, 85: 4842-4846, 1988.
9. Senter, P. D., Schreiber, G. J., Hirshberg, D. L., Ashe, S. A., Hellström, K. E., and Hellström, I. Enhancement of the in vitro and in vivo antitumor activities of phos-phorylated mitomycin c and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res. 49: 5789-5792, 1989.
10. Wallace, P. M., and Senter, P. D. In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate. Bioconjugate Chem. 2: 349-352, 1991.
11. Meyer, D. L., Jungheim, L. N., Law, K. L., Mikolajczyk, S. D., Shepherd, T. A., Mackensen, D. G., Briggs, S. L., and Starling, J. J. Site-specific prodrug activation by antibody-ß-lactamase conjugates: regression and long-term growth inhibition by human colon carcinoma xenograft models. Cancer Res. 53: 3956-3963, 1993.
12. Bosslet, K., Czech, J., and Hoffmann, D. Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res. 54: 2151-2159, 1994.
13. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W., Ullrich, A., and McGuire, W. Human breast can\een correlation of relapse and survival with amplification of the HER-Uneu oncogene. Science (Washington DC), 235: 177-182, 1987.
14. Press, M. F., Pike, M. C., Chazin, V. R., Hung, G., Udove, J. A., Mardowicz, M., Danyluk, J., Godolphin, W., Sliwkowski, M., Akita, R., Paterson, M. C., and Slamon, D. J. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 53: 4960-4970, 1993.
15. Berchuck, A., Kamel, A., Whitaker, R., Kerns, B., Olt, G., Kinney, R., Soper, J. T., Dodge, R., Clarke-Pearson, D. L., McKenzie, M. S., Yin, S., and Bast, R. C. Jr. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50: 4087-4091, 1990.
16. Paterson, M. C., Dietrich, K. D., Danyluk, J., Paterson, A.H.G. Lees, A. W., Jamil, N., Hanson, J., Jenkins, H., Krause, B. E., McBlain, W. A., Slamon, D. J., and Fourney, R. M. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 51: 556-567, 1991.
17. Kern, J. A., Schwartz, D. A., and Nordberg, J. E. p. 85 neu oncogene expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 50: 5184-5191, 1990.
18. Oka, K., Nakano, T., and Arai, T. c-erbB-2 oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer (Phila.), 73: 668-671, 1994.
19. Press, M. F., Cordon-Cardo, C., and Slamon, D. J. Expression of the HER-2/neu proto-oncogene in normal adult and fetal tissue. Oncogene, 5: 953-962, 1990.
20. Styles, J., Harrison, S., Gusterson, B. A., and Dean, C. J. Rat monoclonal antibodies to the external domain of the product of the c-erbB-2 proto-oncogene. Int. J. Cancer, 45: 320-324, 1990.
21. Dean, C., Styles, J., Valeri, M., Modjtahedi, H., Bakir, A., Babich, J., and Eccles, S. Growth factor receptors as targets for antibody therapy. In: A. A. Epenetos and N. R., Lemoine (eds.), Mutant Oncogenes: Targets for Therapy, pp. 27-34. London: Chapman and Hall, 1993.
22. Bakir, M. A., Eccles, S. A., Babich, J. W., Aftab, N., Styles, J. M., Dean, C. J., and Ott, R. W. C-erbB-2 protein overexpression in breast cancer as a target for PET using Iodine-124-labeled monoclonal antibodies. J. Nucl. Med. 33: 2154-2160, 1992.
23. Dean, C., Eccles, S., Valeri, M., Box, G., Allan, S., McFarlane, C. Sandle, J., and Styles, J. Rat mAbs to the product of the c-erbB-2 proto-oncogene for diagnosis and therapy in breast cancer. Cell Biophys. 22: 111-127, 1993.
24. Allan, S. M., Dean C. J., Fernando, I., Eccles, S., Styles, J., McCready, V. R., Baum, M., and Sacks, N. Radioimmunolocalisation in breast cancer using the gene product of the c-erbB-2 as the target antigen. Br. J. Cancer, 67: 706-712, 1993.
25. Mann, J. Haase-Held, M., Springer, C. J., and Bagshawe, K. D. Synthesis of an W-mustard prodrug. Tetrahedron, 46: 5377-5382, 1990.
26. Springer, C. J., CMDA, an antineoplastic prodrug. Drugs Future, 18: 212-215, 1993.
27. Modjtahedi, H., Styles, J., Box, G., Eccles, S., Gusterson, B., and Dean, C. Antitu-mour activity of rat mAbs to the human receptor for EGF. In: A. A. Epenetos and N. R., Lemoine (eds.), Mutant Oncogenes: Targets for Therapy, pp. 35-47. London: Chapman and Hall, 1993.
28. Melton, R. G., Boyle, J.M.B. Rogers, g. T. Burke, P., Bagshawe, K. D., and Sherwood, R. F. Optimisation of small-scale coupling of A5B7-monoclonal antibody to carboxypeptidase G2. J. Immunol. Methods, 158: 49-56, 1993.
29. Fraker, P. J., and Speck, J. C. Protein and cell membrane iodinations with a sparingly soluble chloramide 1, 3, 4, 4-tetra chloro-3-6-diphenyl-glycouril. Biochem. Biophys. Res. Commun. 80: 849-853, 1978.
30. Springer, C. J., Antoniw, P., and Bagshawe, K. D. Endogenous activation of a prodrug in antibody directed enzyme prodrug therapy. In: A. A., Epenetos (ed.), Monoclonal Antibodies-Applications in Clinical Oncology. pp. 185-191. London: Chapman and Hall, 1991.
31. Gullick, W. J., Love, S. B., Wright, C., Barnes, D. M., Gusterson, B., Harris, A. L., and Airman, D. G. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br. J. Cancer, 63: 434-438, 1991.
32. Seshadrí, R. Firgairi, F. A., Horsfall, D. J., McCaul, K., Sctlur, V., and Kitchen, P. Clinical significance of HER-2/niu oncogene amplification in primary breast cancer. J. Clin. Oncology, 77: 1936-1941, 1993.
33. Kallioniemi, O., Holli, K., Visakorpi, T., Koivula, T., Helin, H. H., and Isola, J. J. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survivial in breast cancer. Int. J. Cancer, 49: 650-655, 1991.
34. Gasparini, G., Pozza, F., and Harris, A. L. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J. Natl. Cancer Inst. 85: 1206-1219, 1993.
35. Hynes, N. E. Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor and potential as a target for cancer therapy. Semin. Cancer Biol. 4: 19-26, 1993.
36. Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Säve-Söderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C., Golouh, R., Reed, R., Martinez-Tello, F., Tiltman, A., Torhorst, J., Grigolato, P., Bettelheim, R., Neville, A. M., Bürki, K., Castiglione, M., Collins, J., Lindtner, J., and Senn, H. Prognostic importance of c-iB-2 expression in breast cancer. J. Clin. Oncol. 10: 1049-1056, 1992.
37. Wright, C., Nicholson, S., Angus, B., Sainsbury, J.R.C. Farndon, J., Cairns, J., Harris, A. L., and Home, C.H.W. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br. J. Cancer, 65: 118-121, 1992.
38. Toikhanen, S., Helin, H., Isola, J., and Joensuu, H. Prognostic significance of HER-2 oncoprotein expression in breast cancer; a 30-year follow-up. J. Clin. Oncol. 10: 1044-1048, 1992.
39. Hancock, M. C., Langton, B. C., Chan, T., Toy, P., Monahan, J. J., Mischak, R. P., and Shawver, L. K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of m-diammincdichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 51: 4575-4580, 1991.
40. Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepherd H. M., and Ullrich, A. Monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9: 1165-1172, 1989.
41. Harwerth, I., Wels, W., Schlcgeel, J. Müller, M., and Hynes, N. E. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br. J. Cancer, 68: 1140-1145, 1993.
42. Wels, W., Harwerth, I., Mueller, M., Groner, B., and Hynes, N. E. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res. 52: 6310-6317, 1992.
43. De Santes, K., Slamon, D., Anderson, S. K., Shepard, M., Fendly, B., Maneval, D., and Press, O. Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res. 52: 1915-1923, 1991.
44. Weiner, L. M., Holmes, M., Adams, G. P., Lacreat, F., Watts, P., and Garcia de Plazzo, I., A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-rB-2 and CD16. Cancer Res. 53: 94-100, 1993.
45. Maier, L. A., Xu, F. J., Hester, S., Boyer, C. M., McKenzie, S., Bruskin, A. M., Argon, Y., and Bast, R.C.J. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/mu gene product. Cancer Res. 57: 5361-5369, 1991.
46. Leitzel, K., Teramota, Y., Sampson, E., Mauceri, J., Langton, B. C., Demers, L., Podczaski, E., Harvey, H., Shambaugh, S., Volas, G., Weaver, S., and Lipton, A. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J. Clin. Oncology, 10: 1433-1436, 1992.
47. Sharma, S. K., Bagshawe, K. D., Springer, C. J., Burke, P. J., Rogers, G. T., Boden J. A., Antoniw, P., Melton, R. G., and Sherwood, R. F. Antibody-directed enzyme prodrug therapy (ADEPT): a three phase system. Dis. Markers, 9: 225-231, 1991.
48. Yuan, F., Baxter, L. T., and Jain, R. K. Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res. 57: 3119-3130, 1991.
49. Drebin, J., link, V., and Stern, D. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell, 41: 695-706, 1985.
50. Modjtahedi, H., and Dean, C. J. The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer (Review). Int. J. Oncol. 4: 277-296, 1994.
51. Bagshawe, K. D., Sharma, S. K., Springer, C. J., Antoniw, P., Rogers, G. T., Burke, P. J., Melton, R., and Sherwood, R. Antibody-enzyme conjugates can generate cytotoxic drugs from inactive precursors at tumor sites. Antibody Immunoconj. Radiopharmacol. 4: 915-922, 1991.
52. Bagshawe, K. D., Sharma, S. K., Springer, C. J., and Rogers, G. T. Antibody-directed enzyme prodrug therapy (ADEPT): a review of some theoretical, experimental and clinical aspects. Anal. Oncol. in press, 1994.